(RYAM) Rayonier Advanced Materials - NYSE
Sector: Basic Materials | Industry: Chemicals | Exchange: NYSE (USA) | Market Cap: 548m USD | Total Return: 116.7% in 12m
Avg Turnover: 6.52M
Qual. Beats: 0
Rev. Trend: -91.0%
Qual. Beats: 0
Warnings
High Debt while negative Cash Flow
Interest Coverage Ratio 0.1 is critical
Altman Z'' 0.43 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Rayonier Advanced Materials Inc. (RYAM) is a global manufacturer of cellulose-based products, operating across segments including Cellulose Specialties, Biomaterials, and High-Yield Pulp. The company processes wood fibers into natural polymers used in diverse end-markets such as pharmaceuticals, food thickeners, liquid crystal displays, and automotive components. Its portfolio also extends to commodity-grade viscose for textiles and absorbent fluff pulp for personal hygiene products.
As a specialist in the high-purity cellulose sector, RYAM operates within a capital-intensive industry where market share is often protected by complex chemical processing requirements and high barriers to entry. The company’s biomaterials division reflects a growing industry shift toward circular economy models, converting manufacturing byproducts into biofuels and lignin-based chemicals. For a deeper look into the companys valuation metrics, consider reviewing the latest data on ValueRay.
Headquartered in Jacksonville, Florida, the firm maintains a broad geographic footprint with significant sales exposure to China, Europe, and North America. Its integration into global supply chains ranges from industrial applications like munitions and lacquers to consumer staples such as food packaging and apparel fabrics.
- Cellulose specialty pricing and volume demand drive primary revenue growth
- High energy and chemical input costs impact manufacturing profit margins
- Global textile and construction cycles dictate commodity viscose and pulp demand
- Biomaterials expansion and biofuel production diversify long-term earnings streams
- Significant debt leverage and interest rates influence equity valuation and liquidity
| Net Income: -470.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA -10.67 > 1.0 |
| NWC/Revenue: 10.08% < 20% (prev 10.49%; Δ -0.41% < -1%) |
| CFO/TA 0.01 > 3% & CFO 16.3m > Net Income -470.7m |
| Net Debt (695.5m) to EBITDA (171.7m): 4.05 < 3 |
| Current Ratio: 1.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.1m) vs 12m ago 1.38% < -2% |
| Gross Margin: 6.10% > 18% (prev 9.56%; Δ -3.47% > 0.5%) |
| Asset Turnover: 75.51% > 50% (prev 75.49%; Δ 0.01% > 0%) |
| Interest Coverage Ratio: 0.07 > 6 (EBIT TTM 6.91m / Interest Expense TTM 97.6m) |
| A: 0.09 (Total Current Assets 529.2m - Total Current Liabilities 385.2m) / Total Assets 1.67b |
| B: -0.10 (Retained Earnings -171.0m / Total Assets 1.67b) |
| C: 0.00 (EBIT TTM 6.91m / Avg Total Assets 1.89b) |
| D: 0.16 (Book Value of Equity 229.4m / Total Liabilities 1.43b) |
| Altman-Z'' = 0.43 = B |
| DSRI: 1.16 (Receivables 173.6m/167.3m, Revenue 1.43b/1.60b) |
| GMI: 1.57 (GM 9.56% / 6.10%) |
| AQI: 0.43 (AQ_t 0.10 / AQ_t-1 0.24) |
| SGI: 0.89 (Revenue 1.43b / 1.60b) |
| TATA: -0.29 (NI -470.7m - CFO 16.3m) / TA 1.67b) |
| Beneish M = -2.83 (Cap -4..+1) = A |
As of June 15, 2026, the stock is trading at USD 8.56 with a total of 460,740 shares traded.
Over the past week, the price has changed by +5.68%,
over one month by -7.86%,
over three months by -25.24% and
over the past year by +116.71%.
Rayonier Advanced Materials has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy RYAM.
- StrongBuy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.5 | 69.4% |
P/E Forward = 27.5482
P/S = 0.3765
P/B = 2.3523
P/EG = 2.6265
Revenue TTM = 1.43b USD
EBIT TTM = 6.91m USD
EBITDA TTM = 171.7m USD
Long Term Debt = 735.5m USD (from longTermDebt, last quarter)
Short Term Debt = 28.0m USD (from shortTermDebt, last quarter)
Debt = 763.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 695.5m USD (calculated: Debt 763.4m - CCE 67.9m)
Enterprise Value = 1.24b USD (548.3m + Debt 763.4m - CCE 67.9m)
Interest Coverage Ratio = 0.07 (Ebit TTM 6.91m / Interest Expense TTM 97.6m)
EV/FCF = -14.78x (Enterprise Value 1.24b / FCF TTM -84.2m)
FCF Yield = -6.77% (FCF TTM -84.2m / Enterprise Value 1.24b)
FCF Margin = -5.89% (FCF TTM -84.2m / Revenue TTM 1.43b)
Net Margin = -32.94% (Net Income TTM -470.7m / Revenue TTM 1.43b)
Gross Margin = 6.10% ((Revenue TTM 1.43b - Cost of Revenue TTM 1.34b) / Revenue TTM)
Gross Margin QoQ = -2.38% (prev 8.87%)
Tobins Q-Ratio = 0.75 (Enterprise Value 1.24b / Total Assets 1.67b)
Interest Expense / Debt = 12.78% (Interest Expense 97.6m / Debt 763.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 5.46m (EBIT 6.91m * (1 - 21.00%))
Current Ratio = 1.37 (Total Current Assets 529.2m / Total Current Liabilities 385.2m)
Debt / Equity = 3.33 (Debt 763.4m / totalStockholderEquity, last quarter 229.4m)
Debt / EBITDA = 4.05 (Net Debt 695.5m / EBITDA 171.7m)
Debt / FCF = -8.26 (negative FCF - burning cash) (Net Debt 695.5m / FCF TTM -84.2m)
Total Stockholder Equity = 306.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.87% (Net Income -470.7m / Total Assets 1.67b)
RoE = -153.5% (Net Income TTM -470.7m / Total Stockholder Equity 306.6m)
RoCE = 0.66% (EBIT 6.91m / Capital Employed (Equity 306.6m + L.T.Debt 735.5m))
RoIC = 0.44% (NOPAT 5.46m / Invested Capital 1.24b)
WACC = 10.29% (E(548.3m)/V(1.31b) * Re(10.57%) + D(763.4m)/V(1.31b) * Rd(12.78%) * (1-Tc(0.21)))
Discount Rate = 10.57% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 68.89 | Cagr: 1.20%
[DCF] Fair Price = unknown (Cash Flow -84.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.32 | # QB: 0
Revenue Correlation: -91.04 | Revenue CAGR: -6.77% | SUE: 0.43 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.24 | Chg30d=+18.33% | Revisions=+33% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.06 | Chg30d=-42.11% | Revisions=-33% | Analysts=2
EPS current Year (2026-12-31): EPS=-1.10 | Chg30d=-55.63% | Revisions=-33% | GrowthEPS=+82.3% | GrowthRev=+0.1%
EPS next Year (2027-12-31): EPS=1.09 | Chg30d=-7.63% | Revisions=+0% | GrowthEPS=+198.6% | GrowthRev=+8.1%
[Analyst] Revisions Ratio: +33%